These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 30676622)

  • 1. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
    Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
    JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
    Patel MR; Ellerton J; Infante JR; Agrawal M; Gordon M; Aljumaily R; Britten CD; Dirix L; Lee KW; Taylor M; Schöffski P; Wang D; Ravaud A; Gelb AB; Xiong J; Rosen G; Gulley JL; Apolo AB
    Lancet Oncol; 2018 Jan; 19(1):51-64. PubMed ID: 29217288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
    Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
    Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
    Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
    Chung HC; Arkenau HT; Lee J; Rha SY; Oh DY; Wyrwicz L; Kang YK; Lee KW; Infante JR; Lee SS; Kemeny M; Keilholz U; Melichar B; Mita A; Plummer R; Smith D; Gelb AB; Xiong H; Hong J; Chand V; Safran H
    J Immunother Cancer; 2019 Feb; 7(1):30. PubMed ID: 30717797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
    Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
    Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.
    Keilholz U; Mehnert JM; Bauer S; Bourgeois H; Patel MR; Gravenor D; Nemunaitis JJ; Taylor MH; Wyrwicz L; Lee KW; Kasturi V; Chin K; von Heydebreck A; Gulley JL
    J Immunother Cancer; 2019 Jan; 7(1):12. PubMed ID: 30651126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
    D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
    JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial.
    Guigay J; Lee KW; Patel MR; Daste A; Wong DJ; Goel S; Gordon MS; Gutierrez M; Balmanoukian A; Le Tourneau C; Mita A; Vansteene D; Keilholz U; Schöffski P; Grote HJ; Zhou D; Bajars M; Penel N
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
    Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
    Kelly K; Infante JR; Taylor MH; Patel MR; Wong DJ; Iannotti N; Mehnert JM; Loos AH; Koch H; Speit I; Gulley JL
    Cancer; 2018 May; 124(9):2010-2017. PubMed ID: 29469949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
    Barlesi F; Vansteenkiste J; Spigel D; Ishii H; Garassino M; de Marinis F; Özgüroğlu M; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Ellers-Lenz B; Bajars M; Ruisi M; Park K
    Lancet Oncol; 2018 Nov; 19(11):1468-1479. PubMed ID: 30262187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
    Dirix LY; Takacs I; Jerusalem G; Nikolinakos P; Arkenau HT; Forero-Torres A; Boccia R; Lippman ME; Somer R; Smakal M; Emens LA; Hrinczenko B; Edenfield W; Gurtler J; von Heydebreck A; Grote HJ; Chin K; Hamilton EP
    Breast Cancer Res Treat; 2018 Feb; 167(3):671-686. PubMed ID: 29063313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
    Verschraegen CF; Jerusalem G; McClay EF; Iannotti N; Redfern CH; Bennouna J; Chen FL; Kelly K; Mehnert J; Morris JC; Taylor M; Spigel D; Wang D; Grote HJ; Zhou D; Munshi N; Bajars M; Gulley JL
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32907924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
    Emens LA; Cruz C; Eder JP; Braiteh F; Chung C; Tolaney SM; Kuter I; Nanda R; Cassier PA; Delord JP; Gordon MS; ElGabry E; Chang CW; Sarkar I; Grossman W; O'Hear C; Fassò M; Molinero L; Schmid P
    JAMA Oncol; 2019 Jan; 5(1):74-82. PubMed ID: 30242306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
    Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
    JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.
    Pujade-Lauraine E; Fujiwara K; Dychter SS; Devgan G; Monk BJ
    Future Oncol; 2018 Sep; 14(21):2103-2113. PubMed ID: 29584456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.
    Vaishampayan U; Schöffski P; Ravaud A; Borel C; Peguero J; Chaves J; Morris JC; Kotecki N; Smakal M; Zhou D; Guenther S; Bajars M; Gulley JL
    J Immunother Cancer; 2019 Oct; 7(1):275. PubMed ID: 31651359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
    Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
    Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.